Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+ Key Biosimilars Events of December 2019
Insights+ Key Biosimilars Events of December 2019
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar aflibercept Mylan and Biocon launched its Ogivri (trastuzumab-dkst) in…
January 17, 2020
PharmaShots' Most Read News of 2019
PharmaShots’ Most Read News of 2019
The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…
January 10, 2020
Insights+: COVID-19 Healthcare News Monthly Updates - April 2020
Insights+: COVID-19 Healthcare News Monthly Updates – April 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
January 5, 2020
Insights+: The US FDA New Drug Approvals in November 2019
Insights+: The US FDA New Drug Approvals in November 2019
The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…
December 13, 2019
Insights+ Key Biosimilars Events of November 2019
Insights+ Key Biosimilars Events of November 2019
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…
December 6, 2019
Insights+ Key Biosimilars Events of October 2019
Insights+ Key Biosimilars Events of October 2019
Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics'possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the biosimilar…
November 1, 2019
Insights+ Key Biosimilars Events of September 2019
Insights+ Key Biosimilars Events of September 2019
Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the…
October 4, 2019
Insights+: The US FDA New Drug Approvals in August 2019
Insights+: The US FDA New Drug Approvals in August 2019
The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 31 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entity and 17 Biologics while breaking its past year's records of approval. However, there is a significant…
September 20, 2019
Insights+ Key Biosimilars Events of August 2019
Insights+ Key Biosimilars Events of August 2019
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space…
September 9, 2019
Load more